Stridsklev Solhild, Salvesen Øyvind, Salvesen Kjell Åsmund, Carlsen Sven M, Vanky Eszter
Department of Obstetrics and Gynecology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Int J Endocrinol. 2018 Aug 16;2018:2604064. doi: 10.1155/2018/2604064. eCollection 2018.
The objective of this study was to investigate possible differences in uterine artery pulsatility index (UtAPI) between pregnant women with PCOS and healthy controls and to explore possible effects of metformin on UtAPI. . The study was conducted in a tertiary center. Forty-eight pregnant women diagnosed with PCOS before pregnancy and 124 healthy pregnant women were included. Women with PCOS were randomly assigned to metformin 2000 mg daily or a placebo. UtAPI was measured five times during 1st and 2nd trimesters of pregnancy in women with PCOS and four times in healthy controls. . There was no difference in UtAPI between PCOS women and healthy controls at any point in time ( = 0.34-0.77). In women with PCOS, randomly assigned to metformin 2000 mg or placebo, UtAPI was unaffected by metformin two hours after intake of the first dose of study medication ( = 0.34). All PCOS women, regardless of randomization, had higher UtAPI two hours after intake of study medication and a meal compared to before a meal ( = 0.02). . In the first and second trimesters of pregnancy, there was no difference in UtAPI between women with PCOS and healthy controls. Metformin had no immediate effect on the UtAPI. Interestingly, blood flow decreased after a meal, suggesting that time since last meal should be taken into consideration when interpreting the results of UtAPI measurements in pregnancy. This trial is registered with ClinicalTrials.gov (NCT00466622) Metformin in Pregnant PCOS women (PregMet) (NCT00159536).
本研究的目的是调查多囊卵巢综合征(PCOS)孕妇与健康对照组之间子宫动脉搏动指数(UtAPI)的可能差异,并探讨二甲双胍对UtAPI的可能影响。该研究在一家三级中心进行。纳入了48名孕前被诊断为PCOS的孕妇和124名健康孕妇。患有PCOS的女性被随机分配至每日服用2000毫克二甲双胍或服用安慰剂。在PCOS女性的妊娠第1和第2孕期测量UtAPI 5次,在健康对照组测量4次。在任何时间点,PCOS女性与健康对照组之间的UtAPI均无差异(P = 0.34 - 0.77)。在随机分配至服用2000毫克二甲双胍或安慰剂的PCOS女性中,在服用第一剂研究药物两小时后,UtAPI不受二甲双胍影响(P = 0.34)。所有PCOS女性,无论随机分组情况如何,在摄入研究药物并进食两小时后UtAPI均高于进食前(P = 0.02)。在妊娠的第1和第2孕期,PCOS女性与健康对照组之间的UtAPI无差异。二甲双胍对UtAPI无即时影响。有趣的是,进食后血流减少,这表明在解释孕期UtAPI测量结果时应考虑距上次进餐的时间。本试验已在ClinicalTrials.gov注册(多囊卵巢综合征孕妇使用二甲双胍(PregMet),注册号分别为NCT00466622和NCT00159536)。